Holen Sie sich die Stockscreener-App
50.84
1.99%
0.99
Schlusskurs vom Vortag:
$49.85
Offen:
$49.85
24-Stunden-Volumen:
738.60K
Relative Volume:
1.06
Marktkapitalisierung:
$2.92B
Einnahmen:
$665.13M
Nettoeinkommen (Verlust:
$64.50M
KGV:
44.43
EPS:
1.1442
Netto-Cashflow:
$185.87M
1W Leistung:
-1.57%
1M Leistung:
-1.19%
6M Leistung:
+19.23%
1J Leistung:
+28.61%
1-Tages-Spanne:
$49.46
$51.41
1-Wochen-Bereich:
$49.46
$51.96
52-Wochen-Spanne:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Firmenname
Supernus Pharmaceuticals Inc
Sektor
Telefon
301-838-2500
Adresse
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
50.84 | 2.86B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Fortgesetzt | Jefferies | Buy |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-04-13 | Hochstufung | Jefferies | Hold → Buy |
| 2020-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Fortgesetzt | Jefferies | Hold |
| 2019-11-08 | Herabstufung | Berenberg | Buy → Hold |
| 2019-11-07 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-06 | Herabstufung | Jefferies | Buy → Hold |
| 2018-11-12 | Bestätigt | B. Riley FBR | Buy |
| 2018-01-18 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Hochstufung | Janney | Neutral → Buy |
| 2017-11-08 | Hochstufung | Stifel | Hold → Buy |
| 2017-10-19 | Eingeleitet | FBR & Co. | Buy |
| 2017-09-19 | Herabstufung | Stifel | Buy → Hold |
| 2017-07-17 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Eingeleitet | Janney | Neutral |
| 2017-06-01 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Hochstufung | Jefferies | Hold → Buy |
| 2015-11-05 | Bestätigt | Northland Capital | Outperform |
| 2015-10-28 | Eingeleitet | Northland Capital | Outperform |
Alle ansehen
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Assessing Supernus Pharmaceuticals (SUPN) Valuation After Recent Share Price Momentum And Undervalued Narrative - Sahm
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026 - The Manila Times
Supernus Pharmaceuticals to Announce Fourth Quarter and - GlobeNewswire
Is Supernus Pharmaceuticals Inc. a stock for growth or value investors2025 EndofYear Setup & Smart Swing Trading Techniques - mfd.ru
Published on: 2026-02-12 06:52:58 - mfd.ru
Supernus Pharmaceuticals to Report Q4 and Full Year 2025 Results - Intellectia AI
Is now the right time to enter Supernus Pharmaceuticals Inc.July 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - mfd.ru
Can Supernus Pharmaceuticals Inc. stock sustain institutional interestJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Supernus Pharmaceuticals, Inc. (SUPN): Investor Outlook on CNS Drug Innovator with 19.56% Upside Potential - DirectorsTalk Interviews
Is Supernus Pharmaceuticals (SUPN) Offering Value After Strong Multi Year Share Price Gains - Sahm
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Lupin launches epilepsy drug in US - ET Pharma
Lupin Launches Topiramate Extended-Release Capsules in the United States - The Malaysian Reserve
(SUPN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Strong results lifted Supernus Pharmaceuticals (SUPN) in Q3 - MSN
India's Lupin Launches Seizure Drug Bioequivalent to Supernus Pharmaceuticals' Trokendi XR - marketscreener.com
Patterns Watch: Should I trade or invest in Supernus Pharmaceuticals Inc2025 Key Highlights & Reliable Price Action Trade Plans - baoquankhu1.vn
SupernusOutlook For 2026 Positive, Upholding Buy Rating (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to "Strong Sell" at Zacks Research - MarketBeat
Published on: 2026-01-31 06:25:45 - baoquankhu1.vn
Ruffer LLP Makes New $2.65 Million Investment in Supernus Pharmaceuticals, Inc. $SUPN - MarketBeat
Supernus Pharmaceuticals amends merger agreement to adjust milestone payments - Investing.com
Supernus Revises Merger Milestone Payment Obligations Agreement - TipRanks
Is Supernus Pharmaceuticals Inc. being accumulated by smart moneyJuly 2025 Patterns & Fast Exit and Entry Trade Guides - mfd.ru
Published on: 2026-01-28 12:01:32 - baoquankhu1.vn
Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Teacher Retirement System of Texas - MarketBeat
Analysis Recap: Should you avoid Supernus Pharmaceuticals Inc. stock right nowWeekly Trade Analysis & Risk Managed Trade Strategies - baoquankhu1.vn
Price-Driven Insight from (SUPN) for Rule-Based Strategy - Stock Traders Daily
Recent 3.5% pullback isn't enough to hurt long-term Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders, they're still up 64% over 5 years - simplywall.st
Loss Report: Is Supernus Pharmaceuticals Inc stock forming a triangle pattern2025 Buyback Activity & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Supernus Pharmaceuticals (SUPN) Stock Analysis: Exploring A 22.67% Potential Upside - DirectorsTalk Interviews
Chart Watch: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsRate Cut & Weekly Sector Rotation Insights - baoquankhu1.vn
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Investment Review: Should you avoid Supernus Pharmaceuticals Inc stock right now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
(SUPN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
How Supernus Pharmaceuticals Inc. stock performs after earningsJuly 2025 Pullbacks & Comprehensive Market Scan Insights - Улправда
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cantor Fitzgerald reiterates Overweight rating on Supernus Pharmaceuticals stock By Investing.com - Investing.com UK
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - Улправда
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - Улправда
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Investment Recap: How Supernus Pharmaceuticals Inc stock compares to growth peersProduct Launch & Weekly High Momentum Picks - Bộ Nội Vụ
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Finanzdaten der Supernus Pharmaceuticals Inc-Aktie (SUPN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Supernus Pharmaceuticals Inc-Aktie (SUPN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Option Exercise |
28.82 |
20,000 |
576,500 |
30,496 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer |
Dec 19 '25 |
Sale |
50.41 |
20,000 |
1,008,150 |
15,496 |
1.19%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):